NSE · MONOPHARMA · Pharmaceuticals
Mono Pharmacare Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹169 Cr with net profit ₹3 Cr — a 1.83% net margin, versus 1.99% the period before.
Shareholding
As of 2026-03-31
- Promoter56.72%
- Public43.28%
529 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.91× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #1 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,80,131 Cr | 38.63 | 5.75 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,18,462 Cr | 213.45 | 3.44 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,232 Cr | 20.48 | 4.1 | 18.59% | 18.86% |
| Lupin Limited | ₹1,10,705 Cr | 19.46 | 4.93 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,06,384 Cr | 52.81 | 6.53 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,246 Cr | 88.01 | 18.16 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,553 Cr | 432 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹91,552 Cr | 99.39 | 2.42 | 9.25% | 10.5% |
| Alkem Laboratories Ltd. | ₹69,545 Cr | 294.21 | 5.03 | 16.66% | 15.65% |
| Biocon Ltd. | ₹69,034 Cr | 539.11 | 2.03 | 1.14% | 2.3% |
| Mono Pharmacare Limited(this company) | — | 5.69 | 0.56 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashMono Pharmacare Limited (MONOPHARMA) has a market capitalization of Rs 72 Cr. The company reported revenue of Rs 169.32 Cr and a P/E ratio of 6.14. The book value is Rs 17.66 with an EPS of Rs 1.75. The company's debt to equity ratio stands at 1.6.
Positives
- +Revenue grew 37.6% to Rs 169.32 Cr.
- +The P/E ratio is 6.14, indicating it trades at 6.14 times its earnings per share.
- +Promoter holding of 56.7241% indicates promoters retain a majority stake.
- +Promoter shares pledged are 0%, indicating no shares held by promoters are pledged.
Negatives
- −The debt-to-equity ratio is at 1.6.
- −Return on Equity (ROE) is not available.
- −Profit margin is not available.
- −No quarterly results have been disclosed.
Financial performance
Revenue grew by 37.6% to Rs 169.32 Cr. Net profit also increased from Rs 2.4424 Cr in Mar 2024 to Rs 3.0902 Cr in Mar 2025. Diluted EPS has shown an upward trend, rising from Rs 0.79 in Mar 2023 to Rs 1.75 in Mar 2025. EBITDA also increased from Rs 2.2488 Cr in Mar 2023 to Rs 8.4884 Cr in Mar 2025.
Profitability & returns
The company recorded a Return on Capital Employed (ROCE) of 10.39%. No profit margin or Return on Equity (ROE) figures are available for the company. The dividend yield is also not disclosed.
Balance sheet
The debt-to-equity ratio is 1.6. The book value per share stands at Rs 17.66. Further details regarding assets, liabilities, and other balance sheet components are not available based on the provided data.
Ownership & pledges
Promoter holding is 56.7241% as of March 31, 2026. Public shareholding is 43.2759%. There has been no reported pledge of promoter shares. No DII or FII holdings are present as of March 31, 2026.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.